Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632445 | 1.00 | CHRM1 (0.51) | CHRM1CHRM2CHRM3GBA1KCNH2 | |
| SCHEMBL10049922 | 1.00 | CHRM1 (0.51) | CHRM1CHRM2CHRM3GBA1KCNH2 | |
| SCHEMBL25501634 | 0.94 | CHRM1 (0.47) | CHRM1CHRM2CHRM3GBA1KCNH2 | |
| SCHEMBL14924890 | 0.94 | CHRM1 (0.47) | CHRM1CHRM2CHRM3GBA1KCNH2 | |
| SCHEMBL19834937 | 0.92 | GBA1 (0.46) | CHRM1CHRM2CHRM3GBA1KCNH2 | |
| SCHEMBL19833602 | 0.92 | GBA1 (0.46) | CHRM1CHRM2CHRM3GBA1KCNH2 | |
| SCHEMBL3012066 | 0.89 | CHRM1 (0.42) | CHRM1CHRM2CHRM3GBA1MAOA | |
| SCHEMBL5830706 | 0.88 | — | — | |
| SCHEMBL3562028 | 0.88 | — | — | |
| SCHEMBL3020121 | 0.88 | CHRM1 (0.43) | CHRM1GBA1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163938-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20110124654-A1 | DIAZACARBAZOLES AND METHODS OF USE | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-20110004006-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110004006-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | KCNH2, KCNC1, KCNH3 | CHRM1 1145/4885CHRM2 626/4885CHRM3 227/4885 |
| US-20110124654-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CHRM1 3310/4885CHRM2 3852/4885CHRM3 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.